Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 601–700 of 2,053
Energy Metabolism and Metformin: Effects on Ischemia-Reperfusion Injury in Kidney Transplantation
Nemeth, D. V., Iannelli, L., Gangitano, E., D’Andrea, V., & Bellini, M. I. (2024) · Biomedicines · doi:10.3390/biomedicines12071534 · Cited by 9
“For more than half a century, metformin (MTF, 1,1-dimethylbiguanide hydrochloride) has been, as a monotherapy or in combination with other drugs, a first-line regimen for type 2 diabetes mellitus (T2DM) [1].”
BackgroundInfluentialDemidowich, A. P., Stanback, C., & Zilbermint, M. F. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15190 · Cited by 13
Rallis, S. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s195994 · Cited by 12
Crabtree, T., Adamson, K., Bickerton, A., Evans, A., Phillips, S., Gallagher, A., Larsen, N., Barnes, D., Dhatariya, K., Field, B. C., et al. (2023) · British Journal of Diabetes · doi:10.15277/bjd.2023.418 · Cited by 6
Isaksen, A. A., Sandbæk, A., Skriver, M. V., & Bjerg, L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15230 · Cited by 6
Metabolic Syndrome and Pharmacological Interventions in Clinical Development
Javor, E., Šarčević, D., & Rešić, A. (2024) · Diabetology · doi:10.3390/diabetology5030023 · Cited by 9
Incremental Prognostic Value of a Coronary Heart Disease Polygenic Risk Score in Type 2 Diabetes
Mordi, I. R., Li, I., George, G., McCrimmon, R. J., Palmer, C. N., Pearson, E. R., Lang, C. C., & Doney, A. S. F. (2024) · Diabetes Care · doi:10.2337/dc24-1489 · Cited by 7
Makkar, B. M., Agarwal, S., Seshadri, K., Kesavadev, J., Chawla, M. S., & Saboo, B. (2024) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071241293567 · Cited by 13
“33 A higher level of TIR is associated with a lower level of HbA1c.”
Patel, H., Allen, A., Karl, J. J., Weng, P. J., Stinnett, S. S., Rosdahl, J. A., & Schuman, S. G. (2025) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264241309683 · Cited by 7
“…peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors are recommended therapies for more than 80% of US adults with type 2 diabetes 16,17 ; however, these therapeutics are less likely to be initiated in patients from low socioeconomic backgrounds because of the higher costs.”
Mphasha, M. H., & Vagiri, R. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020624 · Cited by 14
“The quantity and quality of carbohydrates ingested directly influence insulin requirements, making precise insulin dosing a cornerstone of effective diabetes management [51,52].”
A Narrative Review on the Risk Factors and Healthcare Disparities of Type 2 Diabetes
Gkrinia, E. M. M., & Belančić, A. (2025) · Diabetology · doi:10.3390/diabetology6040025 · Cited by 9
“…control, typically defined as a hemoglobin A1c (HbA1c) level of around 53 mmol/mol (7%), is crucial in mitigating the risk and progression of macrovascular complications, such as coronary artery disease and stroke, as well as microvascular complications, including nephropathy and retinopathy [5–9].”
From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care
Shrestha, D., Dhingra, A., Shakya, S., & Tuladhar, J. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01582-6 · Cited by 8
Potential role of polydatin in treating diabetes mellitus and diabetes-related chronic complications
Yasmin, F., & Tang, K. S. (2025) · Bioscience Reports · doi:10.1042/bsr20241307 · Cited by 9
Jogani, V. G., Elfadil, O. M., Varayil, J. E., & Mundi, M. S. (2025) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001294 · Cited by 11
Cohort profile of the Heidelberg study on diabetes and complications HEIST-DiC
Kliemank, E., von Rauchhaupt, E., Seebauer, L., Roshan, M., Ansmann, M., Flegka, V., Schimpfle, L., Tsilingiris, D., Bartl, H., Fleming, T. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-15343-8 · Cited by 7
Liao, J., Wang, L., Duan, L., Gong, F., Zhu, H., Pan, H., & Yang, H. (2025) · BMC Public Health · doi:10.1186/s12889-025-24068-2 · Cited by 9
Wei, Z., Xu, W., Wang, Y., Tian, Y., Wang, Z., Jing, S., Liu, W., Shen, S., Qin, C., Zhang, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02892-5 · Cited by 8
“Major guidelines (ADA/EASD) and evidence distinguish their indications and safety profiles [14, 15].”
Beyond Green: The Therapeutic Potential of Chlorophyll and Its Derivatives in Diabetes Control
Sartore, G., Zagotto, G., & Ragazzi, E. (2025) · Nutrients · doi:10.3390/nu17162653 · Cited by 11
Asrie, A. B., Belete, T. M., Misker, M. F., Beyna, A. T., Ayele, H. S., Tekle, K. G., Milikit, Y. Z., Andargie, E. A., Afework, H. T., Lenjiso, Y. G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0332628 · Cited by 13
“Poor glycemic control is common globally, with only 50% of DM patients having their glucose controlled [7,31,32].”
Wilkinson, M., Rollin, T., Kuriakose, M., Haggerty-Goede, R. A. L., Miller, D. M., & Dunham‐Snary, K. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110370 · Cited by 6
Nikolaidis, C. G., Gyriki, D., Stavropoulou, E., Karlafti, E., Didangelos, T., Tsigalou, C., & Thanopoulou, A. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1701504 · Cited by 9
Metformin Induced Vitamin B12 deficiency: A Cross sectional study. Untangling the connection
Abhijna Ballal, R., Vidyasagar, S., Acharya, V., & Sukumar, C. A. (2025) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514251357419 · Cited by 7
“2) To study the occurrence of diabetic peripheral neuropathy (PN) due to vitamin B12 deficiency in Type 2 diabetics 3) To study the occurrence of macrocytic anemia due to Vitamin B12 deficiency in Type 2 diabetics on metformin.”
Old Drug, New Science: Metformin and the Future of Pharmaceutics
Caturano, A., Nilo, D., Nilo, R., Sircana, M. C., Erul, E., Zielińska, K., Russo, V., Santonastaso, E., & Sasso, F. C. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010077 · Cited by 13
“…can be achieved through combinatorial regimens, using low-dose and/or delayed-release metformin in association with other glucose-lowering agents (such as DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 receptor agonists) to maintain glycemic efficacy while minimizing systemic accumulation [91,92].”
Kristensen, F., Christensen, D. H., Callaghan, B. C., Nielsen, J. S., Andersen, H., Sørensen, H. T., & Thomsen, R. W. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-01262 · Cited by 9
Eshak, N., Irani, A., & Sullivan, M. M. (2026) · Rheumatology · doi:10.1093/rheumatology/keag033 · Cited by 10
Gelhorn, H. L., Osumili, B., Brown, K. E., Ross, M., Schulz, A., Fernandez, G., & Boye, K. S. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s401465 · Cited by 8
“Incretin-based treatments (for example, glucagon-like peptide-1 [GLP-1] receptor agonists(9)) offer improved glycemic control, low risk of hypoglycemia, and the potential for clinically relevant weight loss.(6) Tirzepatide, a novel glucosedependent insulinotropic polypeptide (GIP)/GLP-1 RA, has been approved for the t…”
BackgroundWeight loss to disrupt type 2 diabetes
Alsaqaaby, M. S., & le Roux, C. W. (2023) · Diabetology International · doi:10.1007/s13340-023-00626-0 · Cited by 8
“The American Diabetes Association (ADA) and European Association for Study of Diabetes (EASD) consensus report in 2022 recommended a patient-centred approach when treating diabetes [1].”
BackgroundZhong, P., Tan, S., Zhu, Z., Zhang, J., Chen, S., Huang, W., He, M., & Wang, W. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.04.010 · Cited by 8
He, A., Shi, C., Wu, X., Sheng, Y., Zhu, X., Yang, J., & Zhou, Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01502-5 · Cited by 8
“Sodium–glucose cotransporter 2 (SGLT2) inhibitors prevented progression of CKD in patients with diabetes [35, 36], and evidence suggested that glucagon-like peptide 1 receptor agonists (GLP-1RA) had benefits for the kidney [37].”
BackgroundEhrhardt, N. M., Aroda, V. R., Galindo, R. J., Peters, A. L., & Shubrook, J. H. (2023) · Clinical Diabetes · doi:10.2337/cd23-0047 · Cited by 6
Self-citationKirkman, M. S., Tripputi, M., Krause-Steinrauf, H. J., Bebu, I., AbouAssi, H., Burch, H. B., Duran-Valdez, E., Florez, H. J., Garvey, W. T., Hsia, D. S., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1332 · Cited by 6
Self-citationHoldt‐Caspersen, N. S., Dethlefsen, C., Vestergaard, P., Hejlesen, O. K., Hangaard, S., & Jensen, M. H. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1185 · Cited by 7
Harada, M., Adam, J., Covic, M., Ge, J., Brandmaier, S., Muschet, C., Huang, J., Han, S., Rommel, M., Rotter, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02288-x · Cited by 6
“Clinical guidelines now recommend the use of sodium-glucose-cotransporter-2 inhibitors (SGLT2i) as add-on therapy with metformin to enhance glycemic control [8, 9].”
Tudurachi, B.-S., Anghel, L., Tudurachi, A., Sascău, R. A., Zanfirescu, R.-L., & Stătescu, C. (2024) · Biomedicines · doi:10.3390/biomedicines12061314 · Cited by 7
Boye, K. S., Poon, J. L., Landó, L. F., Sapin, H., Huh, R., Wang, M., WILLIAMSON, S. E., & Patel, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01620-8 · Cited by 8
“Over time, as the disease progresses, intensification of insulin therapy with prandial insulin is often needed to improve glycaemic control [2, 3].”
InfluentialСиманенкова, А. В., Fuks, O., Тимкина, Н. В., Islamova, A., Суфиева, Д. А., Kirik, O. V., Korzhevsky, D. E., Vlasov, T. D., & Каронова, Т. Л. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2907265 · Cited by 7
AlRasheed, A., Hashim, H., & Alrofaie, H. (2024) · Cureus · doi:10.7759/cureus.65545 · Cited by 8
“Effective management of diabetes focuses on maintaining blood glucose levels within a target range to prevent or delay the onset of complications [9].”
BackgroundCurrent and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 9
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
“According to the American Diabetes Association and the European Association for the Study of Diabetes, TZP demonstrates significant efficacy as a post-metformin option for enhancing glycemic management and potentially aiding in weight reduction in overweight or obese patients [128].”
Covenant, A., Yates, T. E., Rowlands, A. V., Dempsey, P. C., Edwardson, C. L., Hall, A. P., Davies, M. J., & Henson, J. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111886 · Cited by 8
Self-citationUyaroğlu, O. A., Ruža, I., Škrha, J., Patoulias, D., Bevc, S., Bojadjiev, B. I., Gómez‐Huelgas, R., Bojunga, J., Leśniak, W., Carretero‐Gómez, J., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.11.018 · Cited by 8
Witek, P., Bolanowski, M., Kretowski, A. J., & Głowińska, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1455465 · Cited by 7
Qin, M., Chao, L., & Liu, S. (2025) · Medicine · doi:10.1097/md.0000000000041061 · Cited by 7
“[22] Severe hypoglycemia was defined by the presence of central nervous system symptoms that required external assistance.”
Pu, Z., Wang, T. B., Lu, Y. Y., Wu, Z., Chen, Y., Luo, Z., Wang, X., & Mou, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479166 · Cited by 8
Bergman, B. K., Rosenstock, J., Garvey, W. T., Batterham, R. L., Chen, Y., Liu, M., Sharma, P., Karanikas, C. A., & Thieu, V. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16337 · Cited by 10
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
Manti, R., Cosmo, S. D., Desenzani, P., Ferrara, L., Girelli, A., Memoli, G., Bisio, A., Braae, U. C., Deinega, A., Berra, C., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01719-6 · Cited by 9
“…statement also suggests that the addition of a new glucose-lowering agent to metformin should be individualized based on patient preferences and clinical characteristics such as established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD) [4, 5].”
Alshaikhi, S. A., Alfaqih, F. H., Alrashdi, A. K., Alamri, F. A., Alzubaidi, A. S., Alnashri, A. I., Alsharidi, B., Alshreef, S. M., Almantashri, A. S., Alshaikhi, O. A., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01894-4 · Cited by 14
“These factors include complications arising from the disease, inadequate control of blood sugar levels, and psychological factors such as depression [10].”
Guo, R., Pandey, A., Chandramouli, C., Wu, M., Cai, A., Liu, Y., Ren, Q. W., Huang, J., Zhang, J.-R., Gu, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16509 · Cited by 5
“11,12 Although comparative studies have shown that SGLT2 inhibitors possess higher glucose-lowering efficacy than DPP-4 inhibitors, 12 there remains a lack of conclusive evidence regarding the superior class for managing HbA1c variability.”
Delgado, E., Morales, C., Abreu, C., Verdugo, A. A., Carbonell, A. M. P., González, A. C., Valero, J. A. G., López, V. G., Rasmussen, C. L., Scheuer, S. H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16523 · Cited by 6
Mortensen, S. R., Pedersen, M. E., Skou, S. T., & Ried‐Larsen, M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20042893 · Cited by 8
Bódis, K. B., Bombrich, M., Schön, M., Knebel, B., Zaharia, O., Bönhof, G. J., Karusheva, Y., Straßburger, K., Kupriyanova, Y., Kotzka, J., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.06.004 · Cited by 8
Ghosal, S., & Sinha, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168755 · Cited by 10
Defining a Continuous Glucose Baseline to assess the impact of nutritional interventions
Chkroun, C., Trouwborst, I., Cherta-Murillo, A., Owen, L., Darimont, C., & Rytz, A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1203899 · Cited by 10
Yoon, E., Bae, J. C., & Suh, S. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1730 · Cited by 8
“MNT provided by a registered dietitian or nutritionist can significantly reduce hemoglobin A1c (HbA1c) and help to prevent, delay and treat complications related with diabetes [7].”
BackgroundMaiorino, M. I., Buzzetti, R., Irace, C., Laviola, L., Napoli, N., Pitocco, D., Esposito, K., & on behalf of LIVE CGM working group (2023) · Endocrine · doi:10.1007/s12020-023-03473-w · Cited by 7
Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes
Vázquez, L. A., Romera, I., Santos, M. R., & Escalada, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01467-5 · Cited by 9
“To achieve weight reduction goals, the recent consensus by the ADA-European Association for the Study of Diabetes (EASD) recommends individualised weight loss goals and consideration of GLP-1 RAs with high weight loss effi-cacy, as they can often provide weight loss of 10–15% or more [3].”
BackgroundInfluentialHollander, P. A., Krause-Steinrauf, H. J., Butera, N. M., Kazemi, E. J., Ahmann, A., Fattaleh, B. N., Johnson, M. L., Killean, T., Lagari, V. S., Larkin, M., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0516 · Cited by 6
Self-citationJi, L., Ahmann, A., Åhrén, B., Capehorn, M., Hu, P., Lingvay, I., Liu, W., Rodbard, H. W., Shen, Z., & SORLI, C. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15309 · Cited by 8
Merker, L., Ebert, T., Schleicher, E. D., Guthoff, M., & Isermann, B. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0202 · Cited by 6
Soetedjo, N. N. M., Permana, H., Hariyanto, T. I., Tendean, M., Kusumawati, M., Ritonga, E., Yanto, T. A., & Suastika, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110984 · Cited by 6
Baskal, S., Posma, R. A., Bollenbach, A., Dieperink, W., Bakker, S. J. L., Nijsten, M. W., Touw, D. J., & Tsikas, D. (2024) · Amino Acids · doi:10.1007/s00726-024-03383-9 · Cited by 6
“The biguanide metformin is the most commonly prescribed oral antihyperglycemic drug to treat type 2 diabetes (Davies et al. 2022).”
BackgroundMetabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice
Harada, M., Han, S., Shi, M., Ge, J., Yu, S., Adam, J., Adamski, J., Scheerer, M. F., Neschen, S., de Angelis, M. H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130962 · Cited by 9
Alqahtani, S. A. M., Alsaleem, M. A., & Ghazy, R. M. (2024) · Medicine · doi:10.1097/md.0000000000037631 · Cited by 8
“[15] Iron is an essential mineral for human health.”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Faggiano, P. M., Fattirolli, F., Frisinghelli, A., Piccioli, L., Dasseni, N., Silverii, M. V., Albricci, L., D'Ambrosio, G., Garrì, R., Esposito, L., et al. (2019) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2019.1040 · Cited by 7
Medidas de prevenção da COVID-19 em pessoas que vivem com diabetes mellitus
Silva, Á. L. D. D. A., Matias, L. D. M., Freitas, J. M. D. S., et al. (2020) · Revista Enfermagem Atual In Derme · doi:10.31011/reaid-2020-v.93-n.0-art.808 · Cited by 6
Đekić, D., Bojić, M., Janež, A., Majanović, S. K., Hadžimušović, I. G., Ković, T., & Mihalevska, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01407-3 · Cited by 6
“Global and regional consensuses or guidelines on diabetes management recommend initiating glucagon-like peptide-1 receptor agonists (GLP-1RAs) as the first injectable therapy and intensifying with a combination injectable therapy (insulin plus GLP-1RAs) if the glycated hemoglobin (HbA1c) remains above the target [5, 6…”
BackgroundScheen, A. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.82 · Cited by 6
Kataoka, Y., Hosoda, K., Makino, H., Matsubara, M., Matsuo, M., Ohata, Y., Koezuka, R., Tamanaha, T., Tomita, T., Honda-Kohmo, K., et al. (2019) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2019.09.02 · Cited by 6
Lei, X., Pu, D., Shan, G., & Wu, Q. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1070 · Cited by 7
Recent advances and ongoing challenges in diabetes prevention and control in China
Geng, T., Yin, X., Guo, Y., Liu, G., Pan, A., & Liao, Y. (2025) · The Innovation · doi:10.1016/j.xinn.2025.101083 · Cited by 12
Liu, Y., Ma, W., Fu, H., Zhang, Z., Yin, Y., Wang, Y., Liu, W., Yu, S., & Zhang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1235639 · Cited by 8
“Therefore, it could be concluded that control of BG and BW is important in the treatment of T2DM (Davies et al., 2022).”
BackgroundHan, K. A., Hwang, Y., Moon, S., Cho, H., Yoo, H. J., Choi, S. H., Chon, S., Kim, K., Kim, T. N., Kang, J. G., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15717 · Cited by 5
“3,4 In the context of the comprehensive management emphasized by recent guidelines, intensified therapy using sodium-glucose co-transporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors may be a useful treatment option.”
Amadi, P. U., Osuoha, J. O., Ekweogu, C. N., Jarad, S., Efiong, E. E., Odika, P. C., Ejiofor, C. C., Aloy-Amadi, O., Gill, G. S., Adumekwe, C. W., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107602 · Cited by 6
Wright, E. E., Shah, V. N., Miller, E. M., Thach, A., Javadi, P., Davies, S., & Sieradzan, R. (2025) · Diabetology · doi:10.3390/diabetology6020013 · Cited by 7
Arecoline Alleviates T2DM via Gut Microbiota Modulation and Liver Gene Regulation in Mice
Xu, M. J., Li, W., Xu, Y., Zhang, J., Xue, H., Du, J., & Hu, X. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70015 · Cited by 6
Mody, R., Desai, K. R., Teng, C., Reznor, G., Stockbower, G. E., Grabner, M., & Benneyworth, B. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16372 · Cited by 9
Badrooj, N., Jayedi, A., & Shab‐Bidar, S. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00818-1 · Cited by 9
Cheng, C., Cui, H., Yu, X., & Li, W. (2025) · Foods · doi:10.3390/foods14111916 · Cited by 9
“Diabetes mellitus, particularly type 2 diabetes, has emerged as a global health crisis, with its prevalence escalating due to lifestyle changes and aging populations [1].”
Early prescription of SGLT2i for acute patient care: from current evidence to future directions
Ricci, F., Saraullo, S., Boccatonda, A., Sorella, A., Cipollone, A., Simeone, P., Gallina, S., Santilli, F., Cipollone, F., & D’Ardes, D. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103081 · Cited by 6
Cazzola, M., Hanania, N. A., Page, C. P., Calzetta, L., Matera, M. G., & Rogliani, P. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2514607 · Cited by 6
“…thiazolidine-diones, dipeptidyl peptidase-4 inhibitors (DPP-4Is), sodium-glucose cotransporter-2 inhibitors (SGLT-2Is), glucagon-like peptide 1 receptor agonists (GLP-1RAs), insulins, α-glucosidase inhibitors, dopaminergic antagonists, bile acid sequestrants, meglitinides, and amylinomimetics [95].”
Sinclair, A. J., Sequiera, I., & Abdelhafiz, A. H. (2025) · Metabolites · doi:10.3390/metabo15060381 · Cited by 9
Wang, J., Qu, J., Ye, M., Feng, R., Hui, X., Yang, X., Jin, J., Tong, Q., Zhang, X., & Wang, Y. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101416 · Cited by 9
“…and miglitol, delay carbohydrate absorption by inhibiting intestinal α -glucosidase enzymes, and they generally do not cause hypoglycemia [36]. v and vi) The remaining two classes act by increasing insulin secretion, either directly (sulfonylureas and glinides) or indirectly via…”
Mateos, I. C., Morales, C., & Aguilera, B. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155434 · Cited by 12
“…for the management of T2D have endorsed a multifactorial and holistic approach with the aim of preventing or delaying CV complications and have highlighted the clinical importance of weight reduction as a pillar of this holistic approach, thus contributing to improving glycemic control [7–10].”
Bramlage, P., Vijayan, A., Varghese, T. P., Sadanandan, D. M., Lanzinger, S., & Rodriguez, C. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70010 · Cited by 7
“16,53,54 These considerations highlight the need for individualized therapy, with GLP-1 RAs as an alternative for those with ASCVD or SGLT2 inhibitor intolerance.”
Physical activity in kidney disease: evidence and implementation
Young, H. M. L., Billany, R. E., Graham-Brown, M. P. M., Lightfoot, C. J., March, D. S., & Smith, A. C. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00999-2 · Cited by 10
“The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) guidelines for the management of type 2 diabetes mellitus have introduced the concept of 24-h movement behaviours into a clinical context 91 .”
Hoog, M. M., Vallarino, C. R., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K. A., & Richard, E. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01794-9 · Cited by 11
“The American Association of Clinical Endocrinology, ADA, and European Association for the Study of Diabetes recognize that achiev‑ ing hemoglobin A1c (HbA1c) targets of ≤ 6.5% and weight loss ≥ 10% can improve long‑term outcomes [12–15].”
InfluentialWu, H.-L., Chen, J., Cata, J. P., Hsieh, C., Cherng, Y., & Tai, Y. (2025) · Anaesthesia · doi:10.1111/anae.70024 · Cited by 9
Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea
Elian, V., Popovici, V., Steriade, A. T., Radulian, G., Ozon, E. A., Moroșan, E., & Muşat, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010234 · Cited by 6
“Metformin is the first-line drug used in treating T2DM, as the American Diabetes Association recommends in Standards of Care in Diabetes (available at https://professional. diabetes.org/standards-of-care, accessed on 26 July 2025) [162].”
Contemporary management of advanced chronic kidney disease: An evidence-based review
Baker, L. W., Ovincy, C., Souvalian, L., Hickson, L. J., & Chebib, F. T. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106557 · Cited by 9
Lipidomic profiling unveils sex differences in diabetes risk: Implications for precision medicine
Pina, A. F., Meneses, M. J., Carli, F., Patrício, B., Ribeiro, R. T., Patarrão, R. S., Gardete-Correia, L., Duarte, R., Boavida, J. M., Raposo, J. F., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70137 · Cited by 8
“The management of T2D requires multifactorial behavioral and pharmacological treatments, not only to prevent or delay complications, but also to maintain quality of life (1).”
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection
Jansz, T. T., Young, K., Hopkins, R., McGovern, A. P., Shields, B. M., Hattersley, A. T., Jones, A. G., Pearson, E. R., Bingham, C., Oram, R. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06577-2 · Cited by 5
“…international guidelines recommend the use of SGLT2 inhibitors in individuals with type 2 diabetes, an eGFR ≥20 ml/min per 1.73 m 2 and chronic kidney disease (CKD): i.e. a reduced eGFR ( 60 ml/min per 1.73 m 2 ) or albuminuria (urinary albumin/creatinine ratio [uACR] ≥3 mg/mmol) [2, 3].”
InfluentialFrom one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?
Koufakis, T., & Busetto, L. (2025) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2025.102589 · Cited by 10
Burhan, A., Subpaiboonkit, R., & Hui-chuan, H. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113103 · Cited by 11
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 12
“In diabetic patients, the progression from MASLD to MASH and advanced fibrosis occurs more rapidly, with a higher risk of cirrhosis and hepatocellular carcinoma (HCC) [35].”
InfluentialPlant-Derived Strategies for Glycemic Management in Diabetes: A Narrative Review
Hušák, V., Shvadchak, V. V., Bobrova, O. M., Faltus, M., Hryhoriv, Y., Karbivska, U., Vatashchuk, M., Hurza, V., & Mel’nyk, V. M. (2026) · Diabetology · doi:10.3390/diabetology7020029 · Cited by 10
“Contemporary guidance therefore emphasizes individualized, combination strategies that address glycemia and cardiometabolic risk across disease stages [5].”
Multiomics: the intersection of personalized nutrition in cardiometabolic diseases
Çelik, E., Koçyiğit, E., Bingöl, F. G., Karaçolak, C., Cemali, Ö., Simonelli, M., Ağagündüz, D., & Capasso, R. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07836-5 · Cited by 8
“This highlighted the translational relevance of PN strategies in routine clinical care, especially when customized to individual preferences, metabolic phenotypes, and comorbidities [160].”
Aroda, V. R., Buzzetti, R., Dalskov, S., Jain, A. B., Larsen, J. S., Mathieu, C., Pratley, R. E., Videmark, A. N., Watt, T., & Buse, J. B. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00126-9 · Cited by 10
Self-citationTramunt, B., Disse, E., Chevalier, N., Bordier, L., Cazals, L., Dupuy, O., Marre, M., Matar, O., Meyer, L., Noilhan, C., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01327-8 · Cited by 7
Inhibitory Effects of Nipa Palm Vinegar on the Carbohydrate Hydrolysing Enzymes
Yasmin, F. Y. F., Meyyammai, S., Razak, K. N. A., Samad, N. B. A., Widyawati, T., & Yusoff, N. A. (2023) · Sains Malaysiana · doi:10.17576/jsm-2023-5203-09 · Cited by 8
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.